Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
Keros Therapeutics will receive a $20 million milestone payment from partner Takeda following the dosing of the first patient in the Phase 3 ELRiSE MDS trial of elritercept. The payment is part of a global license agreement that includes $200 million already received upfront and potential total milestones exceeding $1.1 billion.
Key figures
- Deal Value Usd
- 20000000
- Upfront received
- $200 million
- Milestone potential
- $1.1 billion
- Distribution percentage
- 25%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.